Protalix BioTherapeutics (PLX) Cost of Revenue (2010 - 2026)

Protalix BioTherapeutics' Cost of Revenue history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 49.55% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $22.9 million, a 23.27% decrease from a year earlier, with the FY2025 full-year figure at $27.0 million, up 11.0% from the prior year.
• Cost of Revenue fell to $4.1 million in Q1 2026 per PLX's latest filing, from $4.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $9.5 million in Q2 2024 and bottomed at $2.4 million in Q4 2022.
• The 5-year median for Cost of Revenue is $5.9 million (2025), against an average of $5.8 million.
• Across the five-year window, Cost of Revenue soared 269.46% in 2023 and plunged 56.12% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $2.4 million in 2022, then surged by 269.46% to $8.9 million in 2023, then plunged by 56.12% to $3.9 million in 2024, then climbed by 18.86% to $4.6 million in 2025, then declined by 10.65% to $4.1 million in 2026.
• Per Business Quant, the three latest PLX Cost of Revenue figures stand at $4.1 million (Q1 2026), $4.6 million (Q4 2025), and $8.3 million (Q3 2025).